Previous 10 | Next 10 |
DUBLIN , May 11, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America , effective June 1, 2020. In this role, Ms. Sablich will lead Jazz's newly...
For years, Jazz Pharmaceuticals ' (NASDAQ: JAZZ) success has been almost entirely dependent on that of Xyrem, a narcolepsy drug responsible for more than 70% of the company's revenue. The company's good fortune is likely to come to an end: Recently, Harmony Biosciences , Avadel Pharmac...
DUBLIN , May 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor conferences: BofA Securities Virtual Healthcare Conference on Tuesday, May 12, 2020 at 3:00 ...
The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Jazz Pharmaceuticals (NASDAQ: JAZZ) Q1 2020 Earnings Call May 05, 2020 , 4:30 p.m. ET Operator Continue reading
Jazz Pharmaceuticals (NASDAQ: JAZZ) ended 2019 on a positive note, with shares up 20%. This year has been disastrous, though. Jazz stock is down more than 30%, wiping out all of the 2019 gains and then some. The drugmaker announced its first-quarter results after the market closed on ...
Jazz Pharmaceuticals plc (JAZZ) Q1 2020 Earnings Conference Call May 05, 2020 04:30 PM ET Company Participants Kathy Littrell - Head of Investor Relations Bruce Cozadd - CEO Dan Swisher - President Renee Gala - CFO Rob Iannone - Executive Vice President, R&D Mike Mille...
Gainers: MELI +18.9% . VAPO +15.9% . CLW +10.0% . NTNX +10.0% . AXNX +9.2% . More news on: MercadoLibre, Inc., Vapotherm, Inc., Clearwater Paper Corporation, Stocks on the move, , Read more ...
Jazz Pharmaceuticals (NASDAQ: JAZZ ) Q1 results : More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Jazz Pharmaceuticals (NASDAQ: JAZZ ): Q1 Non-GAAP EPS of $0.45 misses by $0.38 ; GAAP EPS of -$2.82 misses by $1.72 . Revenue of $534.73M (+5.2% Y/Y) misses by $9.82M . Press Release More news on: Jazz Pharmaceuticals plc, Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...